JP4740999B2 - 哺乳類における炎症を軽減するための乳酸菌の選択及び使用 - Google Patents

哺乳類における炎症を軽減するための乳酸菌の選択及び使用 Download PDF

Info

Publication number
JP4740999B2
JP4740999B2 JP2008506408A JP2008506408A JP4740999B2 JP 4740999 B2 JP4740999 B2 JP 4740999B2 JP 2008506408 A JP2008506408 A JP 2008506408A JP 2008506408 A JP2008506408 A JP 2008506408A JP 4740999 B2 JP4740999 B2 JP 4740999B2
Authority
JP
Japan
Prior art keywords
cells
reuteri
inflammatory
lactobacillus
strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2008506408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538288A5 (enExample
JP2008538288A (ja
Inventor
コノリー、イーモン
Original Assignee
バイオガイヤ エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオガイヤ エービー filed Critical バイオガイヤ エービー
Publication of JP2008538288A publication Critical patent/JP2008538288A/ja
Publication of JP2008538288A5 publication Critical patent/JP2008538288A5/ja
Application granted granted Critical
Publication of JP4740999B2 publication Critical patent/JP4740999B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2008506408A 2005-04-15 2006-04-12 哺乳類における炎症を軽減するための乳酸菌の選択及び使用 Expired - Lifetime JP4740999B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/107,438 2005-04-15
US11/107,438 US7344867B2 (en) 2005-04-15 2005-04-15 Selection and use of lactic acid bacteria for reducing inflammation in mammals
PCT/SE2006/000434 WO2006110088A1 (en) 2005-04-15 2006-04-12 Selection and use of lactic acid bacteria for reducing inflammation in mammals

Publications (3)

Publication Number Publication Date
JP2008538288A JP2008538288A (ja) 2008-10-23
JP2008538288A5 JP2008538288A5 (enExample) 2010-12-02
JP4740999B2 true JP4740999B2 (ja) 2011-08-03

Family

ID=37087291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506408A Expired - Lifetime JP4740999B2 (ja) 2005-04-15 2006-04-12 哺乳類における炎症を軽減するための乳酸菌の選択及び使用

Country Status (16)

Country Link
US (2) US7344867B2 (enExample)
EP (1) EP1868622B1 (enExample)
JP (1) JP4740999B2 (enExample)
KR (1) KR101042123B1 (enExample)
CN (1) CN101160134B (enExample)
AU (1) AU2006234793B2 (enExample)
DK (1) DK1868622T3 (enExample)
ES (1) ES2606765T3 (enExample)
HU (1) HUE032297T2 (enExample)
LT (1) LT1868622T (enExample)
MX (1) MX2007012656A (enExample)
PL (1) PL1868622T3 (enExample)
PT (1) PT1868622T (enExample)
RU (1) RU2378370C2 (enExample)
SI (1) SI1868622T1 (enExample)
WO (1) WO2006110088A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
US20110293710A1 (en) * 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
US8785183B2 (en) * 2010-09-21 2014-07-22 Biogaia Ab Active plastic material in oil
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
ES2402014B1 (es) 2011-09-07 2014-02-27 Consejo Superior De Investigaciones Científicas (Csic) Peptido secretado por lactobacillus plantarum con función inmunomoduladora
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
HUE042643T2 (hu) 2012-06-04 2019-07-29 Biogaia Ab Lactobacillus reuteri ATCC PTA 6475 csontveszteség
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
ES2874479T3 (es) * 2014-01-23 2021-11-05 Biogaia Ab Agentes que modulan el dolor gastrointestinal
JP2018510631A (ja) * 2015-03-26 2018-04-19 バイオガイア・エイビーＢｉｏｇａｉａ ＡＢ ヒスタミン産生細菌株及びがんにおけるそれらの使用
US10376563B1 (en) 2016-02-12 2019-08-13 Wisconsin Alumni Research Foundation Methods for systemically delivering polypeptides and microorganisms therefor
HUE062788T2 (hu) 2016-04-15 2023-12-28 Baylor College Medicine Lactobacillus reuteri MM4-1A alkalmazása az autizmus spektrumzavar kezelésében vagy megelõzésében
KR102250597B1 (ko) 2017-11-20 2021-05-11 경희대학교 산학협력단 신규 유산균 및 이의 용도
CN110893195B (zh) * 2019-09-30 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22
EP3897836B1 (en) 2019-11-08 2023-08-16 Biogaia AB Serotonin producing bacteria
CN114196581B (zh) * 2020-12-16 2023-06-13 江南大学 缓解高尿酸血症的罗伊氏乳杆菌ccfm1132及应用
WO2023007468A1 (en) 2021-07-30 2023-02-02 Helaina, Inc. Methods and compositions for protein synthesis and secretion
JPWO2023063314A1 (enExample) 2021-10-11 2023-04-20
KR102752058B1 (ko) * 2023-08-25 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) * 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) * 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5534253A (en) * 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
US5837238A (en) * 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
AU5773600A (en) * 1999-06-30 2001-01-31 Board Of Regents Of The University Of Nebraska, The Method of isolation of regulated virulence determinants from bacterial pathogens
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria

Also Published As

Publication number Publication date
RU2007142174A (ru) 2009-05-20
KR101042123B1 (ko) 2011-06-16
US7344867B2 (en) 2008-03-18
HK1115730A1 (en) 2008-12-05
KR20070121700A (ko) 2007-12-27
WO2006110088A1 (en) 2006-10-19
EP1868622A4 (en) 2011-11-02
ES2606765T3 (es) 2017-03-27
LT1868622T (lt) 2017-01-10
US20060233775A1 (en) 2006-10-19
DK1868622T3 (en) 2017-01-16
CN101160134B (zh) 2012-08-22
EP1868622A1 (en) 2007-12-26
CN101160134A (zh) 2008-04-09
PL1868622T3 (pl) 2017-04-28
US20080107635A1 (en) 2008-05-08
SI1868622T1 (sl) 2017-01-31
PT1868622T (pt) 2016-12-29
AU2006234793A1 (en) 2006-10-19
JP2008538288A (ja) 2008-10-23
EP1868622B1 (en) 2016-09-28
RU2378370C2 (ru) 2010-01-10
MX2007012656A (es) 2007-12-13
HUE032297T2 (en) 2017-09-28
AU2006234793B2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
US20080107635A1 (en) Selection and use of lactic acid bacteria for reducing inflammation in mammals
CN101171019B (zh) 免疫功能调节剂
Zhang et al. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-α–induced interleukin-8 production in caco-2 cells
CA2754300C (en) Bacteria strains having a high anti-inflammatory activity
RU2243779C2 (ru) Штамм молочно-кислых бактерий lactobacillus paracasei cncm i - 2116 (ncc 2461), обладающий способностью предотвращать колонизацию кишечника патогенными бактериями, вызывающими диарею, супернатант его культуры и принимаемое внутрь средство для профилактики и/или лечения нарушений, ассоциируемых с диареей
RU2246956C2 (ru) Штамм бактерий lactobacillus paracasei cncm i-2116 (ncc 2461), обладающий способностью предотвращать заражение эпителиальных клеток кишечника ротавирусами, вызывающими диарею, и средство для лечения и/или профилактики нарушений, ассоциируемых с диареей, вызываемой ротавирусами
EP2220210B1 (en) Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
WO2008079009A1 (en) Immunomodulating probiotic lactic acid bacteria
Kang et al. Leuconostoc citreum HJ‐P4 (KACC 91035) regulates immunoglobulin E in an ovalbumin‐induced allergy model and induces interleukin‐12 through nuclear factor‐kappa B and p38/c‐Jun N‐terminal kinases signaling in macrophages
HK1115730B (en) Selection and use of lactic acid bacteria for reducing inflammation in mammals
KR100887822B1 (ko) 락토바실러스 루테리 균주를 이용하여 포유동물에서 면역기능을 향상시키는 방법
KR100887819B1 (ko) 락토바실러스 루테리 균주를 이용하여 포유동물에서 면역 기능을 향상시키는 방법
McCoy Effects of feeding Lactobacillus reuteri X-18 on blood chemistry and immune parameters in beagle (Canis familiaris) puppies
Gnauck The impact of probiotic bacteria on gene expression of Interleukin-8, Interleukin-17 and CASP3 in Caco-2 cells
Cooper Immunomodulatory effects of lactic acid bacteria on human intestinal epithelial cells and macrophages in the context of a pro-inflammatory challenge
HK1115067B (en) Immune function modulating agent
HK1130284A1 (en) Method for culture of lactic acid bacterium having high immunomodulating activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20101015

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20101026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110419

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110502

R150 Certificate of patent or registration of utility model

Ref document number: 4740999

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140513

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term